Table A2.
Effect of Prognostic Covariates on EFS and OS by Univariate Cox Model
| Variable | No. of Patients | No. of Deaths | EFS |
OS |
||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Whole group | 49 | 30 | 7.9 months (median) | 12.3 months (median) | ||
| Sex (male v female) | 1.04 | 0.54 to 2.03 | 0.98 | 0.47 to 2.05 | ||
| Female | 29 | 18 | ||||
| Male | 20 | 12 | ||||
| Stage (III, IV v I, II) | 1.35 | 0.66 to 2.75 | 1.19 | 0.55 to 2.54 | ||
| I, II | 15 | 10 | ||||
| III, IV | 34 | 20 | ||||
| Extranodal sites of disease (> 1 v ≤ 1) | 2.67* | 1.33 to 5.34 | 3.26* | 1.55 to 6.86 | ||
| ≤ 1 | 35 | 18 | ||||
| > 1 | 14 | 12 | ||||
| “B” symptoms (yes v no) | 0.82 | 0.32 to 2.12 | 2.8 | 0.66 to 11.78 | ||
| Yes | 43 | 28 | ||||
| No | 6 | 2 | ||||
| ECOG PS (2, 3 v 0, 1) | 2.38* | 1.16 to 4.88 | 4.57* | 1.85 to 11.28 | ||
| 0, 1 | 18 | 6 | ||||
| 2, 3 | 31 | 24 | ||||
| Tumor grade (high v intermediate)† | 1.64 | 0.83 to 3.23 | 2.63* | 1.19 to 5.79 | ||
| High | 29 | 21 | ||||
| Intermediate | 20 | 9 | ||||
| Prior thrush (yes v no) | 0.96 | 0.48 to 1.92 | 1.3 | 0.6 to 2.84 | ||
| Yes | 30 | 21 | ||||
| No | 19 | 9 | ||||
| Prior AIDS (yes v no) | 1.39 | 0.66 to 2.9 | 1.4 | 0.62 to 3.15 | ||
| Yes | 33 | 22 | ||||
| No | 16 | 8 | ||||
| Antiretroviral therapy (yes v no) | 0.34* | 0.16 to 0.17 | 0.25* | 0.1 to 0.59 | ||
| Yes | 18 | 7 | ||||
| No | 31 | 23 | ||||
| Hemoglobin (≤ 10.3 v > 10.3 g/dL) | 2.28* | 1.14 to 4.55 | 2.39* | 1.15 to 4.98 | ||
| > 10.3 g/dL | 24 | 13 | ||||
| ≤ 10.3 g/dL | 25 | 17 | ||||
| Serum LDH (n = 35) (> 270 v ≤ 270 U/L) | 1.67 | 0.5 to 5.55 | 2.22 | 0.52 to 9.49 | ||
| > 270 U/L | 31 | 22 | ||||
| ≤ 270 U/L | 4 | 2 | ||||
| IPI (age, stage, PS, ENS; 1 increase of IPI) | 1.75* | 1.22 to 2.51 | 2.1* | 1.4 to 3.16 | ||
| 0 | 6 | 3 | ||||
| 1 | 17 | 7 | ||||
| 2 | 15 | 10 | ||||
| 3 | 11 | 10 | ||||
| HIV score (1 increase of the score) | 1.26 | 0.84 to 1.91 | 1.38 | 0.87 to 2.19 | ||
| 0, 1 | 13 | 6 | ||||
| 2 | 22 | 13 | ||||
| 3 | 14 | 11 | ||||
| ACTG 142 prognostic index (1 increase of the index) | 1.49 | 0.92 to 2.43 | 1.89* | 1.11 to 3.2 | ||
| 0, 1 | 27 | 15 | ||||
| 2 | 15 | 10 | ||||
| 3 | 7 | 5 | ||||
| Second-line mCHOP (yes v no) | 1.29 | 0.62 to 2.69 | 0.46 | 0.18 to 1.21 | ||
| Yes | 11 | 5 | ||||
| No | 38 | 25 | ||||
NOTE. Analysis of the IPI in the table excluded LDH because this was not determined in 14 patients (29%). When analyzed by multivariate Cox model adjusting the effect of baseline LDH (n = 35), the IPI remains significantly associated with EFS (HR = 1.65, P = .012) and OS (HR = 1.72, P = .013).
Abbreviations: EFS, event-free survival; OS, overall survival; IPI, International Prognostic Index; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status; ENS, extranodal sites of disease; ACTG, AIDS Clinical Trials Group; mCHOP, dose-modified cyclophosphamide, doxorubicin, vincristine, and prednisone.
Statistically significant (P < .05).
Tumor grade was based on a composite of confirmed tumor grade and African grade for patients not reviewed or confirmed in the United States.